Keywords:
Breast, Oncology, MR, MR-Diffusion/Perfusion, Diagnostic procedure, Contrast agent-intravenous, Dysplasias, Neoplasia
Authors:
M. Nadrljanski, N. Gusic, Z. Milovanovic, V. Plesinac - Karapandzic, O. Radulovic, Z. C. Milosevich; Belgrade/RS
DOI:
10.1594/ecr2013/C-0868
References
[1] Love SM,
Gelman RS,
Silen W.
Fibrocystic “disease” of the breast – a nondisease? N Engl J Med 1982; 307: 1010–1014.
[2] Guray M,
Sahin AA.
Benign Breast Diseases: Classification,
Diagnosis,
and Management.
The Oncologist 2006; 11: 435–449.
[3] Milošević Z,
Jovanović T.
Fibrocistična bolest dojke.
In: Goldner B,
Milošević Z,
Jovanović T (Eds.) Mamografija u dijagnostici oboljenja dojke.
Beograd: Velarta,
2001; pp 109-128.
[4] Chen JH,
Liu H,
Baek HM,
Nalcioglu O,
Su MY.
MR Imaging Features of Fibrocystic Change of the Breast Magn Reson Imaging 2008; 26: 1207–1214.
[5] Dupont WD,
Page DL.
Risk factors for breast cancer in women with proliferative breast disease.
N Engl J Med 1985; 312: 146–151.
[6] Dupont WD,
Parl FF,
Hartmann WH et al.
Breast cancer risk associated with proliferative breast disease and atypical hyperplasia.
Cancer 1993; 71: 1258–1265.
[7] American College of Radiology (ACR). ACR Breast imaging reporting and data system,
Breast Imaging Atlas.
Reston,
VA: American College of Radiology 4th Edition; 2003.
[8] Partridge SC,
Mullins CD,
Kurland BF,
et al.
Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size.
AJR Am J Roentgenol 2010; 194 (6): 1664–1673.